Latest Breaking News On - Alcohol use disorder - Page 10 : vimarsana.com

Prescribing alcohol use disorder medications upon discharge from alcohol-related hospitalizations works

Prescribing alcohol use disorder medications upon discharge from alcohol-related hospitalizations works
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Harvard universityUnited statesTimothy andersonEdeny bernsteinUniversity of pittsburghCenters for medicare medicaid servicesMedicaid servicesMassachusetts general hospitalGeneral internal medicineOutcomes after initiationAlcohol use disorderHospital discharge

Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 .

United statesBeckley psytechExchange commissionSchizophrenia international researchDemerx ib incHercules capital incSecurities exchangeLife sciencesSociety in florence italy onFlorian brandChief executive officerTreatment resistant depressionAlcohol use disorderMajor depressive disorderPsilocybin therapyPivotal trial

atai Life Sciences Reports Fourth Quarter and Full Year

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment.

United statesBeckley psytechLife sciencesSecurities exchangeSchizophrenia international researchHercules capital incDemerx ib incExchange commissionSociety in florence italy onFlorian brandChief executive officerTreatment resistant depressionAlcohol use disorderMajor depressive disorderPsilocybin therapyPivotal trial

Podcast: Clearmind s Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors - SciSparc (NASDAQ:SPRC), Clearmind Medicine (NASDAQ:CMND)

Mark hadenClearmind medicineAdi zuloff shaniZuloff shaniBenzinga psychedelicsAlcohol use disorderPath for taking

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds

On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC). The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide. These were previously filed as provisional pate

United statesGerd altmanAdi zuloff shaniTrademark officeScisparc ltdMinistry of health israelClearmind medicine incPatent cooperation treatyUnited states patentClearmind medicineStock market gameBenzinga proDay trialIbogaine and ketamine compoundsPatent applicationsClearmind medicine